These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 117024)

  • 21. Bactericidal activity of human sera with a physiologic or genetic defect of the complement system.
    Jankowski S; Grzybek-Hryncewicz K; Kopeć W; Zalewski J; Zielinsk SA
    Acta Microbiol Pol; 1988; 37(3-4):309-15. PubMed ID: 2470241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of mucoidy on antibody coating of Pseudomonas aeruginosa.
    Marrie TJ; Harding GK; Ronald AR; Dikkema J; Lam J; Hoban S; Costerton JW
    J Infect Dis; 1979 Mar; 139(3):357-61. PubMed ID: 109548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effect of Pseudomonas aeruginosa exotoxin on various nonspecific factors of immunologic reactivity in an experiment].
    Dziubak ST
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Jun; (6):69-72. PubMed ID: 6412491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-PcrV titers in non-cystic fibrosis patients with Pseudomonas aeruginosa respiratory tract infection.
    Nagaoka K; Yamashita Y; Kimura H; Kimura H; Suzuki M; Fukumoto T; Hayasaka K; Yoshida M; Hara T; Maki H; Ohkawa T; Konno S
    Int J Infect Dis; 2019 Oct; 87():54-59. PubMed ID: 31419482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Live, attenuated vaccines against Pseudomonas: observations in the experimental animal and the human.
    Bellanti JA; Sordelli DO; Cerquetti MC; Wan KS; Arias G; Cereb N; Zuba D; Kulczycki L; Hooke AM
    Ann Sclavo Collana Monogr; 1986; 3(1-2):247-58. PubMed ID: 3122803
    [No Abstract]   [Full Text] [Related]  

  • 26. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.
    Young LS; Armstrong D
    J Infect Dis; 1972 Sep; 126(3):257-76. PubMed ID: 4626509
    [No Abstract]   [Full Text] [Related]  

  • 27. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 28. Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.
    Young LS
    J Infect Dis; 1972 Sep; 126(3):277-87. PubMed ID: 4626510
    [No Abstract]   [Full Text] [Related]  

  • 29. Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.
    Fick RB; Naegel GP; Matthay RA; Reynolds HY
    J Clin Invest; 1981 Oct; 68(4):899-914. PubMed ID: 6793632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary-tract escherichia coli with cross-reactive antigens to encapsulated pyogenic bacteria.
    Myerowitz RL; Schneerson R; Robbins JB; Turck M
    Lancet; 1972 Aug; 2(7771):250-3. PubMed ID: 4114507
    [No Abstract]   [Full Text] [Related]  

  • 31. Pseudomonas aeruginosa infection and vaccination in the rat.
    Kostiala AA
    J Med Microbiol; 1980 May; 13(2):201-12. PubMed ID: 6770090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa.
    Cachia PJ; Hodges RS
    Biopolymers; 2003; 71(2):141-68. PubMed ID: 12767116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
    Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
    J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody response in patients with Pseudomonas aeruginosa infection to a 'common antigen' from P. aeruginosa analysed by means of quantitative immunoelectrophoretic methods.
    Høiby N; Hertz JB; Sompolinsky D
    Acta Pathol Microbiol Scand C; 1980 Jun; 88(3):149-54. PubMed ID: 6778073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The etiological agent bacteria and the antibodies developed against them in urinary tract infections].
    Koçal N; Atun IH
    Mikrobiyol Bul; 1982 Apr; 16(2):131-42. PubMed ID: 7144623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.
    Moody MR; Kessel RW; Young VM; Fiset P
    Infect Immun; 1978 Sep; 21(3):905-13. PubMed ID: 101467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pseudomonas infections in a hospital. 4. Type specific antibody in human serum].
    Shigeta S; Yasunaga Y
    Nihon Saikingaku Zasshi; 1976 Sep; 31(5):621-8. PubMed ID: 826672
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of prolonged bacteremia on leukocyte bactericidal function.
    Postel J; Furtado D; Schloerb PR
    Surgery; 1977 Feb; 81(2):180-3. PubMed ID: 402038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasion of Haemophilus influenzae and Pseudomonas aeruginosa in humans.
    Suzuki H; Juwono SS; Matsumoto K
    Tohoku J Exp Med; 1985 May; 146(1):105-17. PubMed ID: 3927515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity of gram-negative bacilli to the serum bactericidal activity: a marker of the host-parasite relationship in acute and persisting infections.
    Olling S
    Scand J Infect Dis Suppl; 1977; (10):1-40. PubMed ID: 339328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.